Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 404

Similar articles for PubMed (Select 16197663)

1.

Safety assessment of raloxifene over eight years in a clinical trial setting.

Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.

Curr Med Res Opin. 2005 Sep;21(9):1441-52.

PMID:
16197663
2.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

3.

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.

Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S; Multiple Outcomes of Raloxifene Evaluation Investigators.

Obstet Gynecol. 2004 Oct;104(4):837-44.

PMID:
15458908
4.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.

PMID:
18254988
5.

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.

PMID:
16059623
6.

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.

J Bone Miner Res. 2004 Aug;19(8):1270-5. Epub 2004 Apr 12.

PMID:
15231013
7.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.

PMID:
11261828
8.

Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.

Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K.

Osteoporos Int. 2003 Oct;14(10):793-800. Epub 2003 Aug 29.

PMID:
12955333
9.

Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.

Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.

Clin Cancer Res. 2006 Sep 1;12(17):5242-7.

10.

Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL.

J Fam Pract. 2004 Oct;53(10):789-96. Erratum in: J Fam Pract. 2005 Mar;54(3):276.

PMID:
15469774
11.

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.

Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E.

Am J Cardiol. 2006 Feb 15;97(4):520-7. Epub 2006 Jan 4.

PMID:
16461049
12.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.

Menopause. 2003 Jul-Aug;10(4):337-44.

PMID:
12851517
14.

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.

de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP.

Osteoporos Int. 2011 Feb;22(2):567-76. doi: 10.1007/s00198-010-1302-6. Epub 2010 Jun 10.

PMID:
20535606
15.

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.

Pinkerton JV, Archer DF, Utian WH, Menegoci JC, Levine AB, Chines AA, Constantine GD.

Menopause. 2009 Nov-Dec;16(6):1102-8. doi: 10.1097/gme.0b013e3181a816be.

PMID:
19546825
16.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
17.

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.

Archer DF, Pinkerton JV, Utian WH, Menegoci JC, de Villiers TJ, Yuen CK, Levine AB, Chines AA, Constantine GD.

Menopause. 2009 Nov-Dec;16(6):1109-15. doi: 10.1097/gme.0b013e3181a818db.

PMID:
19543129
18.

Benefits and risks of raloxifene by vertebral fracture status.

Sontag A, Wan X, Krege JH.

Curr Med Res Opin. 2010 Jan;26(1):71-6. doi: 10.1185/03007990903427082.

PMID:
19908937
19.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.

Menopause. 2006 May-Jun;13(3):377-86.

PMID:
16735934
20.

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators.

N Engl J Med. 2006 Jul 13;355(2):125-37.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk